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Background: This study aims to perform a survey on clinical data, sociodemographic and
risk  factors from patients with sporadic colorectal cancer (SCRC) treated between 2004 and
2008  in the Coloproctology Service of a teaching hospital in the North-western region of São
Paulo.
Methods:  We  analyzed 749 medical records. Of these, 460 were from colon cancer patients
and  289 from rectal cancer patients. Most of the individuals had white skin and were aged
over  62 years. The variables that were analyzed included gender, age, skin color, profes-
sional  occupation, alcohol drinking and cigarette smoking, family history of cancer, and
comorbidities.  The identiﬁcation of the clinical-sociodemographic proﬁle and risk factors in
a population with the SCRC the northwest region of São Paulo was performed to collaborate
with  prevention strategies.
Results:  The occurrence of SCRC did not differ much  between genders. The most prevalent
professional  occupations were those related to household chores, agricultural and com-
mercial  activities. Among the comorbidities, hypertension and cholelithiasis were the mostrepresentative. The most common diagnosis method and treatment for the majority of
patients were coloscopy and surgery, respectively. On average, the time of the disease pro-
onths. The median number of lymph nodes excised ranged betweengression  was  eight m11  and 14. The most common metastasis was hepatic.
 The study was carried out at the Faculdade de Medicina de São José do Rio Preto (Famerp), São José do Rio Preto, SP, Brazil.
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Conclusion: The occurrence of colorectal cancer is more frequent in men’s white skin with
aged over 62 years. Professional occupation seems to be more important for those exposed
to carcinogenic agents. This type of tumor mostly affects the distal regions of the colon and
rectum with the occurrence of liver metastasis. The affected individuals usually have low
survival due to its high aggressiveness.
©  2014 Sociedade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. 
Avaliac¸ão  clínica  e  epidemiológica  de  pacientes  com  câncer  colorretal
esporádico
Palavras-chave:
Neoplasias colorretais
Epidemiologia
Fatores  de risco
Sintomas  clínicos
r  e  s  u  m  o
Experiência: O presente estudo tem como objetivo realizar um levantamento de dados clíni-
cos e fatores sociodemográﬁcos e de risco de pacientes com câncer colorretal esporádico
(CCRE) tratados entre 2004 e 2008 no Servic¸o  de Coloproctologia de um hospital-escola na
região Noroeste de São Paulo.
Métodos:  Foram analisados 749 prontuários clínicos. Destes, 460 foram de pacientes com
câncer de cólon e de 289 de pacientes com câncer retal. A maioria dos indivíduos era da
rac¸a  branca, com mais de 62 anos de idade. As variáveis analisadas foram gênero, idade, cor
da pele, ocupac¸ão  proﬁssional, consumo de álcool e tabagismo, história familiar de câncer e
co-morbidades. A identiﬁcac¸ão  do perﬁl clínico-sociodemográﬁco e dos fatores de risco em
uma populac¸ão  com CCRE na região noroeste de São Paulo foi realizada para colaborar com
as estratégias de prevenc¸ão.
Resultados:  A ocorrência de CCRE não diferiu muito entre gêneros. As ocupac¸ões  proﬁssion-
ais mais prevalentes foram as relacionadas aos afazeres domésticos, atividades agrícolas
e comerciais. Entre as comorbidades, hipertensão e colelitíase foram as mais representati-
vas. O método de diagnóstico e de tratamento mais comum para a maioria dos pacientes foi
colonoscopia e cirurgia, respectivamente. Em média, o tempo de progressão da doenc¸a  foi de
oito meses. O número mediano de linfonodos extirpados variou entre 11 e 14. A metástase
mais comum foi a hepática.
Conclusão:  A ocorrência de câncer colorretal é mais frequente em homens de pele branca
com idade superior a 62 anos. A ocupac¸ão  proﬁssional parece ser mais importante para
as pessoas expostas a agentes cancerígenos. Este tipo de tumor afeta principalmente as
regiões distais do cólon e do reto, com a ocorrência de metástases no fígado. Geralmente, os
indivíduos afetados exibem baixa sobrevida, devido à alta agressividade dessa neoplasia.
©  2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
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poradic colorectal cancer (SCRC) is a term for malignant neo-
lasms  that are not a familial or inherited disease, which occur
n  the large intestine (colon) and rectum.1 It often develops
nitially as an adenomatous polyp.2–6
This type of cancer is the second most common in
estern countries.3,7 In 2012, a study conducted by the Brazil-
an  National Cancer Institute (BNCI) reported an estimated
18,510 new cases of cancer in the country. Of these, approxi-
ately  30,000 were  colorectal cancer. It ranks ﬁfth as the most
requent  cause of death in Brazil. Approximately 14,180 cases
n  men  and 15,960 cases in women  are newly diagnosed each
ear.1
The carcinogenesis of colorectal and rectum cancers
nvolve the interaction between environmental and geneticfactors.8,9 Some risk factors are well-established, such as age
over  50 years,1,9–12 lifestyle habits, such as highly saturated
fatty acid diet and red meat,1,3,7,8,10 alcohol consumption, and
smoking,2,8,9,11 besides comorbidities, such as cholelithiasis,
metabolic syndrome, and diabetes.
Signs and symptoms of colorectal cancer occur according
to  the anatomical region affected. SCRC also depends on its
physiology  and clinical parameters such as size, extent, and
spread  of the neoplasia. It is a characteristic of this tumor to
present  intestinal obstruction, bleeding (hematochezia, enter-
orrhagia),  change in bowel habits, and systemic settings such
as  signiﬁcant weight loss.1,3,12,13
The prevention of sporadic SCRC involves three phases
of  action in health as follows: the primary phase aims to
prevent  the development of the disease, such as eating an
adequate  diet, physical exercise training, and absence of
tobacco  and alcohol consumption5,12; the secondary phase
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Table 1 – Percent distribution of occupational activities.
Occupation Frequency (n) Percentage (%)
Domestic services 279 37.24
Agricultural 130 17.35
Commercial 94 12.55
Metallurgy 55 7.34
Construction civil 45 6.00
Administrative 43 5.74
Driver 40 5.34
Divers 28 3.73
No information 35 4.67218  j coloproctol (rio 
is the prevention through an early diagnosis by means
of  a physical examination performed by a proctologist,
laboratory tests (fecal occult blood test, carcinoembryonic
antigen CEA test), and imaging screenings (colonoscopy,
proctosigmoidoscopy)1,3; and the tertiary phase is the pre-
vention  of sporadic SCRC with relief of the symptoms and
prevention  of consequences.7
In Brazil there is a shortage of detailed population data
in  SCRC. Therefore the present study aims establish the
clinical–sociodemographic proﬁle and risk factors in a pop-
ulation  with the SCRC the northwest region of São Paulo to
collaborate  with prevention strategies.
Methods
The study was  approved by the Local Ethics Committee (CEP)
–  São José do Rio Preto Medical School – FAMERP (n◦216/2009).
Were  included in the study, the clinical reports of all
patients who had a clinical diagnosis and/or histopatholog-
ical of colon cancer by the physician in Coloproctology Service
of  a university hospital in the region northwest of São Paulo.
Were  excluded patients having family members diagnosed
with  cancer or cases of hereditary colorectal cancer, according
to  evaluation of Coloproctology service.
The variables that were analyzed included gender, age,
skin  color, professional occupation, alcohol drinking and
cigarette  smoking and comorbidities. Skin color was classi-
ﬁed  as white or non-white; we considered individuals whose
skin  color was  non-white as Grayish-browns, Blacks and
Yellows.
We  considered smokers those patients who smoked over a
100 cigarettes and alcoholics those patients who drank more
than  four drinks per week for six months or longer.8
By analysing the medical records, we obtained the follow-
ing  clinical data: symptomatology, comorbidities, primary site
of tumor, location of the tumor that were classiﬁed in the
large  intestine as either proximal (cecum, ascending or trans-
verse  colon) or distal (descending colon, sigmoid, rectosigmoid
junction or rectum), clinical stage, level of histologic differ-
entiation,  and patient survival. Staging of Dukes is classiﬁed
in  Stage A (growth limited to the wall of the rectum with-
out  extension to outside the rectal tissues and without lymph
nodes  metastasis), Stage B (growth extends through the wall
in  the outside the rectal tissues, but the lymph nodes are free
of  metastasis), Stage C (lymph nodes involved with tumor) and
stage  D (distant metastasis).14
Astler-Coller considers staging in Stage B1 and B2 (respec-
tively,  incomplete and complete penetration of the muscularis
propria),  B3 (complete penetration of the distal muscularis
propria), Stages C1 (absence of lymph nodes), C2 (presence
of  lymph nodes), C3 (presence of lymph nodes affected in
the  ligation point proximal vascular) and stage D (distant
metastasis).14
Currently the classiﬁcation adopted in accordance with the
International  Union Control Cancer (UICC), issued in 2002, the
clinical  staging (TNM), used to analyze the aggressiveness of
tumors,  is divided into stages I through IV. Tumors were clas-
siﬁed  according to the TNM following three criteria: tumorTotal 749 100 (99.96)
extent (T), presence of lymph node involvement regional (N)
and  presence of distant metastasis (M).14,15
The data were analyzed by descriptive statistics, using the
Excel  software (version 2007).
Results
We analyzed the medical records of 749 patients. Of these, 460
were affected by colon cancer (Group I) and 289 by rectal cancer
(Group  II).
Group  I was composed of 212 women  (46.08%) and 248 men
(53.91%).  Group II included 135 women  (46.71%) and 154 men
(53.28%).  The mean age at diagnosis for colon cancer patients
and  rectal cancer patients was  63 years (±14.7) and 62.6 (±14.5)
years,  respectively.
Regarding skin color, the group of colon cancer patients
included 181 white individuals (91.87%), while in the group of
rectal  cancer patients, only 54.63% were white.
The assessment of the patients’ professional occupation
showed a higher frequency of individuals whose working
activities related to household chores (37.24%), agricultural
(17.35%) and commercial activities (12.55%). The percentages
allocated to the occupation activities are shown in Table 1.
Smoking  habit was  observed in 26.90% and 26.82% of the
patients  in Groups I and II, respectively. Alcohol addiction cor-
responded  to 20.81% in the ﬁrst and 20.48% in the second
group.
The  most common symptoms presented by patients with
colon  cancer were  intestinal obstruction (10%), bleeding
(8.91%), and abdominal pain (8.26%). Among those who  pre-
sented  neoplasia in the rectum, bleeding (32.17%), diarrhea
(14.53%), and weight loss (8.99%) where predominant (Table 2).
The  most prevalent comorbidities are shown in Table 3.
In  which the most frequent was  the systemic hypertension
present in patients with colon cancer (17.82%) and in patients
with  rectal cancer (26.29%) followed by cholelithiasis, 9.78%
and  21.79%, in patients with cancer of the colon and rectum,
respectively.
The  occurrence of cancer according to the primary tumor
site  was predominant in the rectum (41.70%). Signs and symp-
toms  vary according to the anatomical region.
Regarding diagnosis, colonoscopy was the most method
used  in 54.31% of the colon cancer patients, the remaining
patients received a diagnosis by rectosigmoidoscopy or an
emergency  surgical procedure. Among the patients diagnosed
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Table 2 – Signs and symptoms reported in the ﬁrst consultation, in accordance with the anatomical groups.
Signs and symptoms Colon Rectum
Frequency (n) Percentage (%) Frequency (n) Percentage (%)
Bleeding 41 8.91 93  32.17
Abdominal pain 38 8.26 10 3.46
Diarrhea 22 4.78 42 14.53
AA Obstructive 46 10 13 4.49
Weight loss 21 4.56 26 8.99
Stools tape 6 1.30 6 2.07
AA Inﬂammatory 6 1.30 0 0
Anemia 7 1.52 0 0
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ith colon cancer, 75.70% had neoplasms in stage III and
V  equally distributed by gender of which about one third
ied.  For individuals with rectum cancer, colonoscopy was  the
ethod  of diagnosis of 52.68% of patients. Of these, 62.96%
ad  tumors in stages I and II equally distributed by gender of
hich  44.11% of the patients died.
The mean age of the patients at death was  67.8 years
±15.21) and 68 years (±15.34) in Groups I and II, respectively.
he  time between diagnosis and death was  correspondingly 4
nd 5 months (±8.31) and 9.8 months (±12.25) in Groups I and
I,  respectively.
The coexistence of cancer and adenoma was  identiﬁed in
6  and 27 patients in Groups I and II, respectively. The pre-
ominant  histological type was  the adenocarcinoma, which
epresented 88.83% of colon cancers and 93.65% of rectal
ancers. In some cases, histological identiﬁcation was  not pos-
ible.
Regarding the treatment, surgery was  performed in 77.15%
f  patients in the ﬁrst group and 65.85% in the second group. In
ddition, chemotherapy was  performed using 5-ﬂuorouracil in
ombination with folinic acid in 47.20% and 55.12% of patients
n  Groups I and II, respectively.
The  initial clinicopathological stages (TNM) of colon and
ectal  cancers are shown in Table 4. The median number of
ymph  nodes parched during surgery for histopathological
nalysis was  14 and 11 in colon and rectal surgery, respectively.
The  main sites of dissemination of patients who presented
etastatic colon cancer were liver (64.51%), peritoneum
19.35%), and lung (9.67%); among the metastases observed in
ectal cancer patients, the liver was  also the most affected
rgan  (54.11%), followed by the peritoneum (12.94%), lung
Table 3 – Comorbidities in patients with cancer of the colon and
Comorbidities Colon 
Frequency (n) Percent
HAS 82 17.
DM-2 30 6.
Cholelithiasis 45 9.
Diverticular disease 38 8.
Renal cyst 33 7.
Hepatic steatosis 28 6.
HAS, hypertension arterial systemic; DM-2, diabetes mellitus.(11.76%), bone (8.23%), central nervous system (5.88%), and
urinary  system (7.05%).
Discussion
Our ﬁndings showed that the occurrence of SCRC did not differ
between  gender, which corroborates other studies that also
report  a similar distribution between men  and women1,5,6,16;
although  Santos et al.5 observed a higher incidence of colon
cancer  in women and rectal cancer in men.5
Steele et al.16 reported a predominance of occurrence of
SCRC  in white-skinned individuals with percentage raging up
to  80%. Our study found similar results in relation to colon
cancer  (91.87%) and showed a smaller percentage (54.63%) in
rectal cancer. Other studies have shown a higher incidence
and  survival of sporadic SCRC among African-Americans.16,17
It is worth mentioning that the Brazilian population, which is
representative of our study, has an ethnic composition with
great  conﬂuence of several other ethnic groups, making it dif-
ﬁcult to analyze the inﬂuence of this variable.
It is established in the literature the age of 50 years as risk
factor  for developing sporadic SCRC.1,5,9,10,12,18 Corroborated
with the literature, in our study, the mean age at diagnosis
was  63 years (±14.7) for patients with colon cancer and 62.6
years  (±14.5) for patients with rectal cancer.
Regarding the professional occupation, our data showed
a  predominance of SCRC in those who perform activities
related to household chores, agricultural and commer-
cial  activities. In fact, the exposure to some carcinogenic
agents used in agriculture, and in some industries is
 rectum.
Rectum
age (%) Frequency (n) Percentage (%)
82 76 26.29
52 17 5.88
78 63 21.79
26 32 11.07
1 25 8.65
08 37 12.80
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Table 4 – Adenocarcinoma of colon and rectum and clinicopathological staging.
Variable Colon Rectum
N % N %
TNM
T Is 3 0.65 0
1 17 3.69 14 4.84
2 57 12.39 40 13.84
3 210 45.65 79 27.33
4 28 6.08 7 2.42
NI 145 31.52 149 51.55
N 0 197 42.82 92 31.83
1 95 20.65 28 9.68
2 57 12.39 21 7.26
NI 111 24.13 148 51.21
M 0 224 48.69 98 33.91
1 146 31.73 72 24.91
NI 90 19.56 119 41.17
Duke
A 18 3.91 42 14.53
B 123 26.73 28 9.68
C 87 18.91 27 9.34
D 147 31.95 70 24.22
NI 85 18.47 122 42.21
Astler-Coller
A 13 2.82 13 4.49
B1 41 8.91 29 10.03
B2 82 17.82 28 9.68
B3 2 0.43 0 0
C1 20 4.34 6 2.07
C2 62 13.47 20 6.92
C3 7 1.52 0 0
D 146 31.73 71 24.56
NI 87 18.91 122 42.21Is, in situ; NI, no information.
related to the SCRC, such as dichlorodiphenyltrichloroethane
(DDT), dichlorodiphenyldichloroethylene (p,p′-DDE), and poly-
chlorinated biphenyl (PCB).19 In our study, however, the
investigation of such exposures was  not possible.
Several etiological factors resulting from the interaction of
environmental and genetic factors are involved in the devel-
opment  of colon and rectal cancers. Among them we can
mention  family history, alcohol drinking and smoking,3,8,9 a
highly  saturated fat diet and red meat,1,6,20 and the pres-
ence of comorbidities, such as cholelithiasis,20–22 metabolic
syndrome,23 type II diabetes,20,24,25 and obesity.26,27
Smoking habit is a risk factor for SCRC,28,29 and its occur-
rence seems to reﬂect more  on the building up of the amount
of  yearly exposure than on the time of exposure,29–31 espe-
cially  in rectal cancer.31 Alcohol drinking increases the risk
of  developing SCRC in individuals who drink 30–45 g/day,
and  especially those who  ingest more  than 45 g/day.32 An
increased  risk of those who drink more  than 100 g/week33
has also been demonstrated. Genetic polymorphisms of
enzymes  that act on the metabolism of ethanol, folate,
and  DNA repair together, these factors may  determine a
genotoxic  effect and also act as a solvent to tobacco car-
cinogens and also, which might induce the production
of free radicals34 and decrease the absorption of folate
in  alcoholics;32 also, they would stimulate the productionof  free radicals34 and decrease the absorption of folate
in  alcoholics.32 Smoking and drinking were  observed in
our  study; however, it was not possible to determine the
amount  of exposure due to the retrospective nature of the
study.
Regarding  the diet, although studies are still controversial,
it  is notoriously known that fruits, leguminous plants, green
vegetables,  and dairy products play a protective role against
cancer  of the alimentary system. On the other hand, excessive
intake  of meat and animal fat is not recommended.1,7,9 We did
not  evaluated the food habits in our study. As it is a review of
medical  records, these do not show this information.
Among other comorbidities associated with the develop-
ment  of sporadic SCRC are hyperinsulinemia, obesity,24,25 and
metabolic  syndrome.23 The latter is also related to a higher
incidence of liver metastasis and tumor recurrence. It also is
a probable independent factor of worse prognosis in survival
of  patients with this type of neoplasm.35
In our study, cholelithiasis was  one of the most prevalent
comorbidities; however, the association between cholecystec-
tomy  and SCRC is contradictory in the literature. Goldacre
and  colleagues22 did not observe this association, while other
studies  have found it,20,22 especially in women.20 It was  not
possible to identify the relationship with cholelithiasis in the
researched  literature.
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The weight gain in both gender has been associated with
n  increased risk of SCRC, although the body mass index
ncrement does not seem to contribute to the development
f  this neoplasia.21,27 Thus, it becomes important to identify
ndividuals with metabolic syndrome. They may  represent a
opulation susceptible to the development of SCRC. In our
tudy,  we  were unable to assess the frequency of metabolic
yndrome among those who  developed this type of neoplasia.
Regarding the most affected anatomical region, our study
ound  a higher incidence of SCRC in the rectum, which
s  consistent with the ﬁndings of other studies.5,6 As each
natomical region presents distinct embryological develop-
ent  and physiology when exposed to carcinogens, the
echanism of development of neoplasia as well as the symp-
oms  presented by the patient in each anatomical segment
s  peculiar to their location. Thus, the correct identiﬁcation
f  the primary site of tumor development is of vital impor-
ance  to assist in the choice of treatment among the different
herapeutic approaches.36
Symptoms of SCRC are expressed according to tumor
ocation in association with the anatomy and physiology
f  the affected region, such as an obstruction, bleeding
hematochezia, enterorrhagia), change in bowel habits, and
igniﬁcant  weight loss,1,3,12,13,37 and these symptoms may
elp in the early detection of this neoplasm.38 In this study,
s  found in the literature, the most common symptoms
resented by patients with colon cancer were intestinal
bstruction, rectal bleeding, and abdominal pain.1,37,38
Colonoscopy is an important additional test for the detec-
ion  of SCRC and as well as of its precursor lesion, the
denoma. When identiﬁed at an early stage, a ﬁve-year sur-
ival  appears to be greater than 90%.37,39,40 Some protocols,
uch as the EPAGEII, which was  developed in Europe, deter-
ine  the screening method to be performed. It is based on
he  symptomatology as well as on the presence of risk factors
nd  age of the patient.39 Thus, coloscopy, the gold standard
or  detection of SCRC, acts at the secondary prevention level of
ancer,39,40 and it represents an important tool used in public
ealth  programs. In this study, 54.31% of patients with colon
ancer  and 52.68% of patients with rectal cancer were sub-
ected  to this test. This percentage reﬂects the fact that the
ajority  (75.70%) of them was  referred to the Coloproctology
ervice in an advanced stage of the neoplastic process (T3 and
4).
The  predominant histological malignant neoplasm type
n  our study was  the adenocarcinoma (88.83% of colon can-
ers  and 93.65% of rectal cancers). It is responsible for
ore  than 90% of the cases reported in the literature.2,3
ecause the adenoma is typically a premalignant lesion,36
ts early detection is of utmost importance, since it is an
ndependent risk predictor for the SCRC.41 Other histological
alignant neoplasm types, including mucinous adenocar-
inoma (17%), of which 2–4% are squamoussignet-ring cell
arcinoma, squamous cell carcinoma, and undifferentiated
arcinoma.3
Among the therapeutic options available for colorectal
ancer, chemotherapy stands out, whose toxicity is variable
ccording to the agent applied and that can decrease the
uality  of life of patients in relation to psychological and
hysical  activity.42,43 Currently, the public health network;3 4(4):216–223  221
uses an association between 5-ﬂuorouracil and folinic acid-
leucovorin.38 This drug therapy has been associated with
improved survival and decreased tumor recurrence in patients
undergoing this therapeutic regimen.36,43,44 Although there
are  other drugs that have shown a signiﬁcant improvement in
these patients’ survival, such as the bevacizumab.36,42,43 In our
study,  47.20% of the colon cancer patients and 55.12% of the
rectal  cancer patients underwent chemotherapy using mainly
5-ﬂuorouracil and folinic acid.
Another therapeutic method used is the surgical resection
of  the tumor associated with the removal of lymph nodes
for  adequate staging.40 International consensus and scientiﬁc
papers  recommend an evaluation of at least 12 regional lymph
nodes  in the anatomical sample during the curative treatment
by  surgery, in order to obtain more  reliable data for the appro-
priate  clinical staging.18,45 In our study, we  observed that the
procedure  performed at our institution is in accordance with
that  established in the literature, since the median number of
lymph  nodes resected was  14 in colon surgery and 11 in rectal
surgery.
Regarding  the systemic dissemination of colon and rectal
cancers,  the literature indicates that the main mechanism of
tumor  spread occurs via a hematogenous pathway and, to a
lesser extent, by the lymphatic route with possible implan-
tation  of tumor cells in organs such as liver, lungs, bones,
cerebrum, ovaries, and skin.2,18 Additionally, the dissemina-
tion of neoplastic cells can occur by continuity, which happens
through  the wall of the organs.2,12,19 In this study, we found a
higher  incidence of liver metastases, followed by those affect-
ing  the peritoneum, lung, bones, central nervous system, and
urinary  system.
In  2004, Tucunduva et al.46 conducted a study with non-
oncologists physicians at a health service in order to assess
their  knowledge and attitude toward preventive measures
for  the most common cancers. It was  highlighted that these
physicians  showed interest in the prevention of various
cancers, but they had difﬁculty in carrying out the counsel-
ing  recommended by the consensus.47 Thus, the study of
colorectal  cancer is relevant because a better knowledge of
preventive  measures, risk factors, associated signs and symp-
toms,  research methods, and appropriate time for referral to
specialists, including general practitioners contribute to the
reduction  of survival morbidity and improve public health and
quality  of life.
Conclusion
Malignant tumors SCRC treated in the Coloproctology Service
at  a university hospital in the northwest of São Paulo occur
more  frequently among individuals over 62 years of age,
especially in men  with white skin and with professional
activities of agricultural, commercial and domestic. The most
frequent  comorbidities were hypertension and cholelithiasis.
The  distal regions of the colon and rectum were  the most
affected, with prevalence of hepatic metastasis. The high rate
of patients with stages III and IV indicated late demand in
treatment  centers, which reﬂects the need for preventive edu-
cation campaigns in order to achieve early diagnosis of the
disease.
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